II. Indications
- Emesis of central cause
III. Mechanism
- Centrally acting non-Phenothiazine Antiemetic
-
Dopamine 2 Antagonist
- Active at the ChemoreceptorTrigger Zone in the Medulla of the Brainstem
IV. Dosing
- Adults
- Dose: 300 mg orally or 200 mg IM every 6 to 8 hours
- Child (15 to 41 kg)
- Dose: 100-200 mg orally three to four times daily
- Child (<15 kg): Avoid
V. Safety
- Pregnancy Category C
- Unknown safety in Lactation
- Reduce dose in renal dysfunction and older patients
VI. Resources
- Trimethobenzamide (DailyMed)
VII. References
- Johnson (1993) Harriet Lane, Mosby, p. 521
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C100146 |
SnomedCT | 14814001, 372657005 |
LNC | LP19504-7, MTHU010019 |
English | trimethobenzamide, trimethobenzamide [Chemical/Ingredient], TRIMETHOBENZAMIDE, Trimethobenzamide, Trimethobenzamide (product), Trimethobenzamide (substance) |
Spanish | trimetobenzamida (producto), trimetobenzamida (sustancia), trimetobenzamida |
Ontology: Tigan (C0733768)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C100146 |
English | Tigan, tigan, Monarch brand of trimethobenzamide monohydrochloride |